drugset / Trial / NCT01672554

Clinical Benefits of Seroquel XR in Anxiety Disorder

NCT01672554

NaSingle-groupOpen-labelTreatment

Summary

This research will explore whether Quetiapine XR used primarily to treat psychosis may also cover for comorbid anxiety disorder and offer advantages in patients with schizophrenia and comorboid anxiety disorder. Preliminary data on pharmacological properties of Quetiapine and its metabolites and intuitive impression from our clinical experience lead to believe that Seroquel XR use in monotherapy may offer advantages over other antipsychotics in treating co-morbid anxiety disorder in patients suffering from schizophrenia. This open label switch study conducted in a schizophrenic population intends to verify this hypothesis.

Timeline

Start
2008-12
Primary completion
2012-04
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 400 mg
Subject Quetiapine Small molecule 600 mg
Subject Quetiapine Small molecule 800 mg

Indications